悪性神経膠腫(Malignant Glioma)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Malignant Glioma Overview 8
Therapeutics Development 9
Pipeline Products for Malignant Glioma – Overview 9
Pipeline Products for Malignant Glioma – Comparative Analysis 10
Malignant Glioma – Therapeutics under Development by Companies 11
Malignant Glioma – Therapeutics under Investigation by Universities/Institutes 13
Malignant Glioma – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Malignant Glioma – Products under Development by Companies 17
Malignant Glioma – Products under Investigation by Universities/Institutes 18
Malignant Glioma – Companies Involved in Therapeutics Development 19
Advantagene, Inc. 19
Eli Lilly and Company 20
iDD biotech SAS 21
Lipopharma Therapeutics SL 22
Merck & Co., Inc. 23
Nuo Therapeutics, Inc. 24
Orbus Therapeutics, Inc. 25
Sanofi 26
Stemline Therapeutics, Inc. 27
ZIOPHARM Oncology, Inc. 28
Malignant Glioma – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Ad-RTS-IL-12 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ALD-451 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Dendritic Cell Therapy for Malignant Gliomas – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Dendritic Cell Therapy for Oncology – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Dendritic Cell Therapy for Oncology – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Dendritic Cell Therapy for Oncology – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
eflornithine hydrochloride – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
galunisertib – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GliAtak – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IDD-004 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
LD-224 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
marizomib – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Minerval – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
pembrolizumab – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SL-701 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecule for Brain Cancer and Malignant Glioma – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Vaccine to Target Survivin for Malignant Glioma – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Vaccine to Target Wilm’s Tumor 1 for Oncology – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
voxtalisib – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Malignant Glioma – Recent Pipeline Updates 70
Malignant Glioma – Dormant Projects 84
Malignant Glioma – Discontinued Products 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87